Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2022 07:30 ET | Source: HCW Biologics, Inc

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
May 13, 2022 07:15 ET | Source: HCW Biologics, Inc

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel...
May 05, 2022 07:30 ET | Source: HCW Biologics, Inc

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells Without Using Feeder CellsSufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy Cytokine-Based Fusion Proteins to...
April 19, 2022 07:33 ET | Source: HCW Biologics, Inc

HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022

Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer Debut of preclinical data related to age-associated diseases MIRAMAR, Fla.,...
March 28, 2022 07:00 ET | Source: HCW Biologics, Inc

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

$56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023 FDA Clearance for Initial Clinical Trials in Two Difficult-to-Treat Cancer Indications Publication of Three...
March 24, 2022 08:00 ET | Source: HCW Biologics, Inc

HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest

MIRAMAR, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel...
January 24, 2022 07:00 ET | Source: HCW Biologics, Inc

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein

MIRAMAR, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to...
January 20, 2022 08:00 ET | Source: HCW Biologics, Inc

HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens

MIRAMAR, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to...
January 19, 2022 08:00 ET | Source: HCW Biologics, Inc

HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022

MIRAMAR, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel...
January 06, 2022 07:33 ET | Source: HCW Biologics, Inc

HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022

MIRAMAR, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to...